Biography
Interactions between skeletal muscle and the immune system. A major project in our lab concerns the pathophysiology of muscular dystrophy (dystrophinopathy). Our research has shown that the immune system plays an important role in influencing the severity of muscular dystrophy, and that immune-based interventions can significantly reduce dystrophic muscle pathology and promote muscle regeneration. Our continuing efforts are directed toward identifying the key effector cells and molecules involved in influencing the course of the disease, and examining the interplay between those effectors. Our technical approaches include the generation and analysis of transgenic, dystrophic mice so that the effects of increased or decreased expression of selected effector molecules can be assessed. We also examine the systemic effects of experimental depletions of selected immune cell populations and the efficacy of selected, pharmaceutical interventions on the progress of the disease. In other studies, we are studying the mechanisms through which the immune system influences the wasting of skeletal muscle that occurs during aging, a process called sarcopenia. We are particularly interested in identifying the mechanisms through which specific populations of myeloid cells affect muscle wasting and regeneration, and identifying strategies to slow the wasting process.
Publications
A selected list of publications:
Biography
Dr. Waschek is a Professor of Psychiatry and Biobehavioral Science at the David Geffen School of Medicine at the University of California at Los Angeles (UCLA), and is an expert in the molecular and cellular biology and physiological actions of neuropeptides. Dr. Waschek received a Ph.D. in Pharmaceutical Chemistry in 1984 from the University of California at San Francisco, after which he took a postdoctoral position at the National Institutes of Health (NIH). In 1988 he came to UCLA, where his research has centered on three broad, but related topics: 1) CNS development, degeneration, injury, and repair, 2) neuroinflammatory conditions such as multiple sclerosis, and maternal inflammation-induced perinatal white matter disease, and 3) brain tumor pathogenesis. A past and continuing objective has been to better understand the biological roles of neuropeptides in these processes, especially the two related peptides PACAP and VIP (pituitary adenylyl cyclase activating peptide and vasoactive intestinal peptide, respectively). A major contribution in this area was his discovery first reported in 1998 that PACAP and functional PACAP receptors are highly expressed in the murine neural tube and other germinal centers, and that PACAP acts in part via cAMP and protein kinase A to regulate neural patterning and proliferation via antagonism of hedgehog signaling. Using gene targeting and other approaches, he found this interaction to be relevant not only during brain development, but also in the pathogenesis of malignant pediatric brain tumors. In other work, he has demonstrated growth factor-like actions of PACAP in the maturation of white matter (myelin) and in axon regeneration after injury. Most recently, he determined that VIP and PACAP are critically involved in inflammatory responses after nerve injury and in other pathologies such as lung and liver injury, colitis, cystitis, viral infection, and in an animal model of multiple sclerosis. These studies have revealed significant effects of PACAP and VIP PACAP loss on innate cellular responses to injury, as well as in Th1, Th2, and Th17 differentiation, regulatory T cell production, and immune cell invasion of the CNS parenchyma. Has been continuously funding for his research by the NIH since 1984, and is also currently receiving funding through major grants from the National Institutes of Health, the National Multiple Sclerosis Society, the Department of Defense, and the Simons Foundation. Dr. Waschek has served on NIH study sections almost continuously since 2006, and served as an external reviewer for the newly-formed LOWEE Institute on Tumors and Inflammation in Marburg, Germany, and a consultant for the Japanese-Israeli Scientific and Technological Cooperation Agreement in Life Sciences in the Topic of Stem Cell Research.